Altaris to acquire Simulations Plus in $375m all-cash deal
Pharmaceutical Business Review
Under the deal, Simulations Plus shareholders will receive $18.50 per share, representing a 26% premium to the 60-day volume-weighted average price as of 15 June 2026.
pharminent
June 17, 2026 (Last updated: June 17, 2026)
Pharmaceutical Business Review
Under the deal, Simulations Plus shareholders will receive $18.50 per share, representing a 26% premium to the 60-day volume-weighted average price as of 15 June 2026.
